Are you Milton Wetaka?  Claim your profile  Publications (1)9.37
Total impact    • [show abstract] [hide abstract]     ABSTRACT:
Cotrimoxazole prophylaxis prolongs survival and prevents
opportunistic infections, malaria, and diarrhea in persons
infected with human immunodeficiency virus (HIV). Many countries
recommend that individuals taking antiretroviral therapy (ART)
discontinue cotrimoxazole when CD4 counts are >200 cells/μL.
However, this practice has not been evaluated in sub-Saharan
Africa. Patients in the Home-Based AIDS Care program in eastern
Uganda initiated ART if they had a CD4 cell count ≤250 cells/μL
or World Health Organization stage III or IV HIV disease. In the
program's fourth year, patients with CD4 counts >200 cells/μL
were randomly assigned, by household, to continue or discontinue
cotrimoxazole. Consenting participants were followed for
episodes of malaria and diarrhea. At randomization, 836 eligible
patients had been receiving ART for a mean of 3.7 years, with a
median CD4 count of 489